Parathyroid Hormone Promotes Human Umbilical Vein Endothelial Cell Migration and Proliferation Through Orai1-Mediated Calcium Signaling

Shuhao Wang1†, Lijie Xu1†, Yv Wu1,2, Hailong Shen1, Zhangying Lin1, Yang Fang3, Lesha Zhang3, Bing Shen3, Yehai Liu1* and Kaile Wu1*

1 Department of Otorhinolaryngology, Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China, 2 Department of Otorhinolaryngology, General Hospital of Anhui Wanbei Coal Power Group, Suzhou, China, 3 Department of Physiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China

Parathyroid hormone is the main endocrine regulator of extracellular calcium and phosphorus levels. Secondary hyperparathyroidism–induced endothelial dysfunction may be related to calcium homeostasis disorders. Here, we investigated the effects of parathyroid hormone on human umbilical vein endothelial cells (HUVECs) and characterized the involvement of store-operated Ca2+ entry (SOCE) and the nuclear factor of activated T cells (NFAT) signaling pathway. We used immunoblot experiments to find that parathyroid hormone significantly enhanced the expression of the Orai1 channel, a type of channel mediating SOCE, SOCE activity, and Orai1-mediated proliferation of HUVECs but did not increase Orai2 and Orai3. RNA-seq was utilized to identify 1,655 differentially expressed genes (823 upregulated and 832 downregulated) in parathyroid hormone–treated HUVECs as well as enhanced focal adhesion signaling and expression levels of two key genes, namely, COL1A1 and NFATC1. Increased protein and mRNA expression levels of COL1A1 and NFATC1 were confirmed by immunoblotting and quantitative RT-PCR, respectively. Cytosol and nuclei fractionation experiments and immunofluorescence methods were used to show that parathyroid hormone treatment increased NFATC1 nuclear translocation, which was inhibited by a calcineurin inhibitor (CsA), a selective calmodulin antagonist (W7), an Orai channel inhibitor (BTP2), or Orai1 small interfering RNA (siRNA) transfection. Parathyroid hormone also increased COL1A1 expression, cell migration, and proliferation of HUVECs. The PTH-induced increase in HUVEC migration and proliferation were inhibited by CsA, W7, BTP2, or COL1A1 siRNA transfection. These findings indicated that PTH increased Orai1 expression and Orai1-mediated SOCE, causing the nuclear translocation of NFATC1 to increase COL1A1 expression and COL1A1-mediated HUVEC migration and proliferation. These results suggest potential key therapeutic targets of Orai1 and the downstream calmodulin/calcineurin/NFATC1/COL1A1 signaling pathway in parathyroid hormone–induced endothelial dysfunction and shed light on underlying mechanisms.
INTRODUCTION

Cardiovascular disease (CVD) is the leading cause of death among patients with chronic kidney disease (1). Owing to kidney disease, immune functions decline and various bodily functions are impaired, often accompanied by a variety of complications. A common complication of chronic kidney failure is secondary hyperparathyroidism (SHPT). SHPT is an independent risk factor for cardiovascular events and death in patients, seriously affecting survival rates and patient quality of life. SHPT is clinically characterized by parathyroid hyperplasia and excessive secretion of parathyroid hormone (PTH) (2–4). Elevated PTH may cause severe bone damage and the occurrence of CVD. Vascular dysfunction is a key link in the occurrence of CVD. Although the pathogenesis of this dysfunction is not fully understood, endothelial dysfunction is considered to be a crucial factor in this process (5, 6).

PTH is an 84 amino acid polypeptide hormone that mainly functions as a mediator of bone remodeling and is an important regulator of calcium (Ca\(^{2+}\)) homeostasis (5). Increased intracellular Ca\(^{2+}\) concentration ([Ca\(^{2+}\)]\(_i\)) regulates various functions of cells, including growth, proliferation, differentiation, migration, and death. PTH receptors are distributed throughout the cardiovascular system, including on smooth muscle cells, endothelial cells, and cardiomyocytes (7, 8). Several studies have reported that endothelial dysfunction associated with SHPT may be related to the dysfunction of Ca\(^{2+}\) homeostasis in endothelial cells (9, 10). Store-operated Ca\(^{2+}\) entry (SOCE) activity plays an important role in the occurrence and development of CVD. In SOCE, G-protein coupled receptor activation generates phospholipase C and subsequent inositol triphosphate (IP\(_3\)) production. IP\(_3\) acts on IP\(_3\) receptors located in the endoplasmic reticulum membrane to induce Ca\(^{2+}\) release from Ca\(^{2+}\) stores. Eventually, Ca\(^{2+}\) stores are depleted and this depletion activates stromal interaction molecule 1 (STIM1) to polymerize and move close to the cell plasma membrane to activate Orai channels, which mediate Ca\(^{2+}\) influx to replenish the exhausted Ca\(^{2+}\) stores. There are three types of Orai channels, Orai1, Orai2, Orai3, and two types of STIMs, STIM1 and STIM2. The Orai1 channel is activated by STIM1 (11, 12). Sustained SOCE activity is critical for activating nuclear factor of activated T cells (NFAT) in T lymphocytes, a family of transcription factors that was initially thought to regulate the expression of early immune response genes. NFAT is composed of five family members: NFATC5 is regulated by osmotic pressure, and NFATC1-4 is mainly regulated by the calcium-calcineurin signaling pathway. At rest, NFAT exists in the cytoplasm in a phosphorylated state that can be translocated to the nucleus for transcriptional regulation after activation and dephosphorylation. Although it has been reported that SOCE activity is critical for the activation of the NFAT signaling pathway in endothelial cells, the role this pathway plays in the effects of PTH on endothelial cells is unclear (13–15).

Collagen type I α 1 (COL1A1) is a member of collagen family and collagen is the most abundant protein of extracellular matrix (ECM) being naturally present in human tissues such as skin, bones, cartilage, tendon and ligaments. This biopolymer interacts with cells and regulates cell anchorage, migration, proliferation and survival (16, 17). In the cardiovascular system, COL1A1 and its related signaling pathways are primarily associated with cardiac development and a variety of diseases processes. Furthermore, previous studies have shown that Ca\(^{2+}\) can regulate the expression of COL1A1 through the calcineurin/NFAT pathway in chondrocytes and cardiovascular system, involving in related diseases development and progression (18, 19). Therefore, endothelial damage may be associated with COL1A1 and the calcineurin/NFAT pathway signaling pathway.

In the present study, using pharmacological and molecular tools as well as functional assays, we elucidated the contribution of SOCE activity to PTH-induced intracellular Ca\(^{2+}\) mobilization and downstream cytokine production, providing a new potential target and theoretical basis for the treatment and prevention of CVD caused by SHPT.

MATERIALS AND METHODS

Cell Culture and SiRNA Transfection

HUVECs were purchased from Guandao Biotechnology Co., LTD (Shanghai, China) and cultured in RPMI-1640 medium (Biological Industries, Israel) supplemented with 10% fetal bovine serum, 100 U/mL penicillin G, and 100 U/mL streptomycin sulfate at 37°C in a humidified atmosphere containing 5% CO\(_2\). For experiments, HUVECs were cultured in media containing different concentrations of PTH (C600082, Sangon Biotech, Shanghai, China) for 24 h.

HUVECs were seeded in 12-well plates and grown to 60% confluence for transfection. The cells were then transfected with Orai1 siRNA (200 nM) using lipofectamine 3000 and OptimEM (31985088, Thermo Fisher Scientific, USA) according to the manufacturer’s instructions. Scrambled siRNA was used as a negative control. The siRNA sequence against human Orai1 (5′-GCACAGAUACCAGAAACUUUU-3′) was chemically synthesized by Biosics Biotechnology Co., LTD (Shanghai, China).

Western Blotting

For fractionation experiments, the separation and preparation of cytoplasmic and nuclear extracts from HUVECs were conducted according to the manufacturer’s protocol (P0028, Beyotime, Shanghai, China). The extracted proteins were separated by
sodium dodecyl–sulfate polyacrylamide gel electrophoresis using 10% gels and transferred to polyvinylidene fluoride membranes. After being blocked in 5% skim milk, the membranes were incubated with primary antibodies, including rabbit anti-pNFATC1 (1:1,000, Affinity Biosciences, China), rabbit anti-NFATC1 (1:500, Affinity Biosciences, China), mouse anti-Lamin B1 (1:5,000, Affinity Biosciences, China), and rabbit anti-tubulin (1:5,000, Affinity Biosciences, China).

For immunoblot experiments, total protein was extracted from HUVECs. Protein-transferred membranes were incubated with the primary antibodies rabbit anti-Orai1 antibody, rabbit anti-Orai2 antibody, rabbit anti-Orai3 antibody (1:1,000 dilution; Affinity Biosciences, China) and rabbit anti-STIM1 antibody (1:1,000 dilution; Santa Cruz Biotechnology, USA) at 4°C for 1 h. The protein signal was detected using an ECL detection system (Peiqing Technology, China). The optical density of each blot was normalized to that of β-tubulin or GAPDH and expressed as relative optical density. The blot images were analyzed using ImageJ (National Institutes of Health, Bethesda, Maryland).

**Quantitative Real-Time PCR (qPCR)**

Total RNA was isolated using Trizol reagent (AC0101-B, SparkJade, China) according to the protocol supplied by the manufacturer. The concentration and quality of samples were analyzed using a Nanodrop 1000 system. Afterwards, cDNA was synthesized using the appropriate RNA with the TaqMan® Reverse Transcription kit (AG0304-B, SparkJade, China). Quantitative real-time PCR was performed using Taqman Gene Expression PCR Master Mix (AH0104-B, SparkJade, China). Quantitative real-time PCR was performed with the TaqMan® Reverse Transcription kit (AG0304-B, SparkJade, China), mouse anti-Lamin B1 (1:5,000, Affinity Biosciences, China), and rabbit anti-tubulin (1:5,000, Affinity Biosciences, China).

Cell Viability Assay

HUVECs were seeded in 96-well plates and incubated at 37°C for 24 h. Cell viability was measured using a cell counting assay kit (CCK-8, Dojindo Molecular Technologies, MD, Japan) according to the manufacturer's instructions. Cells were treated with 100 pM PTH or underwent Orai1 siRNA transfection for 24 h before 10 μL of CCK-8 solution was added to each well. After 2 h at 37°C, absorbance at a wavelength of 450 nm was measured with an automatic enzyme-labeling instrument (Rayto, Shandong, China).

Migration Assays

HUVECs were seeded in 12-well plates at a density of 2.0 × 10^5/cm^2 and cultured to confluent monolayers for 24 h. For COL1A1 siRNA experiments, the cells were pre-transfected with siRNA for 24 h. A 200-μL pipette tip was used to create scratch “wounds.” The cells were washed with PBS twice to remove cell debris and incubated in the control medium containing PTH (100 pM) for 24 h. Scratch-wound healing was then observed, and images of the same location along the scratched edges were captured at 0 and 24 h. ImageJ was used to measure the healed area of the scratch and to quantitatively assess the speed of cell migration.

Transcriptome Sequencing and Data Analysis

HUVECs were treated with PTH (100 pM) for 24 h, and four biological repeats were used in the experiments. After RNA extraction, HUVEC transcripts were obtained by cDNA library construction and sequencing. Fast QC software (21) was used to evaluate sequence quality. The index was established using Bowtie software, and transcript expression levels of samples from each of the four groups were analyzed to compare differences between each of two groups by using the edgeR package (22). The Metascape database was used to analyze and annotate enrichment of the functional pathways for the proteins encoded by the DEGs (21). KEGG pathway analysis of the DEGs was carried out in the same database.

Statistical Analysis

Data are expressed as means ± SEM, and all data were analyzed using GraphPad Prism, version 7 software (GraphPad Software, San Diego, California). Statistical evaluation of the data was performed by using the unpaired Student's t-test and one way analysis of variance followed by Dunnett’s multiple
comparisons test. A two-sided value of \( P < 0.05 \) was considered statistically significant.

**RESULTS**

**Effects of PTH on SOCE-Related Protein Expression and Proliferation of Human Umbilical Vein Endothelial Cells (HUVECs)**

After treating HUVECs with different PTH concentrations (1, 10, or 100 pM) for 24 h, we used Western blotting to investigate the change in the expression levels of Orais, which are major components of the channel in SOCE. Our results showed that treatment with PTH at a concentration of 100 pM, but not 1 or 10 pM, significantly increased the protein expression level of Orai1 (Figures 1A, B) and STIM1 (Figures 1F, G). By contrast, Orai2 and Orai3 protein expression levels were not affected by any tested concentration of PTH (Figures 1A, C, D). In addition, the expression of PTH receptor was not affected by PTH treatment in HUVECs (Supplementary Figure 1). The viability of HUVECs was determined using the CCK-8 assay. Compared with controls, treatment of PTH at 100 pM also enhanced the proliferation of HUVECs (Figure 1E).

**FIGURE 1** | Effects of parathyroid hormone (PTH) on Orai expression and proliferation of human umbilical vein endothelial cells (HUVECs). (A–D) Representative Western blot images (A) and summary data (B–D) showing Orai1, Orai2, and Orai3 expression level changes in HUVECs after PTH treatment (1, 10, 100 pM) for 24 h compared with the vehicle control (Con). (E) Summary data showing viability of HUVECs treated with PTH (100 pM) for 24 h. (F, G) Representative Western blot images (F) and summary data (G) showing STIM1 expression level changes in HUVECs after PTH treatment (1, 10, 100 pM) for 24 h compared with the vehicle control (Con). Data are shown as the mean ± SEM; \( n = 3–5 \). * \( P < 0.05 \), ** \( P < 0.01 \) vs. Con analyzed by one-way analysis of variance followed by Dunnett’s multiple comparisons test.
Role of Orai1-Mediated Ca\(^{2+}\) Influx in PTH-Induced HUVEC Proliferation

Orai1 is an ion channel subunit that is a key mediator of SOCE in nonexcitable cells (11). To investigate the role of Orai1-mediated SOCE in the effect of PTH on HUVEC proliferation, we first treated HUVECs with 100 pM PTH for 24 h and determined SOCE activity. As shown in Figures 2A,B, SOCE was evoked by 2 µM thapsigargin (TG), an endoplasmic reticulum Ca\(^{2+}\)-ATPase inhibitor, to deplete endoplasmic reticulum Ca\(^{2+}\) stores in a Ca\(^{2+}\)-free solution, which was achieved by the addition of 2 mM Ca\(^{2+}\) to the extracellular bath solution. The Ca\(^{2+}\) influx was significantly increased in PTH-treated cells compared with control cells, and this effect was inhibited by both the Orai nonspecific inhibitor BTP2 and Orai1-specific small interfering RNA (siRNA) (Figures 2B–E). The ability of the siRNA to reduced Orai1 expression was confirmed by Western blotting (Figures 2F,G). In addition, PTH treatment for 24 h significantly enhanced basal [Ca\(^{2+}\)]\(_i\) in HUVECs (Supplementary Figure 2). We also investigated whether the PTH-induced proliferation and viability increase of HUVECs
was mediated by Orai1. Our data showed that compared with the transfection of scrambled siRNA, Orai1-specific siRNA Orai1 protein knockdown markedly reduced the proliferation and viability of HUVECs in both control and PTH-treated groups (Figure 2H). No significant difference was found between the control and PTH-treated groups in Orai1-specific siRNA transfected cells. These results suggested that PTH increased SOCE activity and proliferation of HUVECs via Orai1-mediated Ca^{2+} signaling.

**PTH-Induced Transcriptome Profile Change of HUVECs**

To identify the underlying molecular mechanisms associated with PTH effects on HUVECs, we assessed gene expression changes using RNA sequencing (RNA-seq) techniques. As shown in the volcano plot and statistical graphs of Figures 3A,B, we detected 1,655 genes, including 823 upregulated genes and 832 downregulated genes, with fold changes ≥2 in the PTH-treated group compared with the control group. Among these differentially expressed genes (DEGs), 1,112 were protein-coding RNAs, 45 were long non-coding RNAs (lncRNA), and 498 were to be experimentally confirmed, nonsense-mediated decay, and processed transcripts (Figure 3C). The heat map in Figure 3D shows that the expression profiles of select genes were that significantly changed in HUVECs.

**Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Analysis**

All DEGs were assessed using KEGG enrichment analysis. The top 20 signaling pathways ranked by P value are shown in Figure 4. Among them, the top three signaling pathways were protein digestion and absorption, ECM-receptor interaction, and...
focal adhesion. Many studies have reported that dysregulation of focal adhesion is closely associated with endothelial dysfunction (23, 24), such as migration and hyperproliferation. Therefore, further analyses were focused on the focal adhesion pathway. We found six DEGs, including COL1A1, PDGFRA, COL6A2, COL6A3, COL1A2 and THBS2, that were involved in the focal adhesion pathway. Of these six DEGs, the expression level of COL1A1 was highest. Previous studies have reported that the COL1A1 gene plays important roles in cell migration and proliferation (25, 26). Therefore, we next assessed the mRNA expression level of COL1A1 by using quantitative polymerase chain reaction (qPCR) assays. Our data showed that the level of COL1A1 mRNA expression was significantly increased in the PTH-treated group compared with the control group (Figure 5A). We also investigated the involvement of NFATC1 in cell migration and proliferation and found that NFATC1 was significantly increased in the PTH-treated groups (Figure 5B). In addition, our data also showed that the mRNA expression levels of Orai1 (Figure 5C) and STIM1 (Figure 5F) were significantly increased, but Orai2 (Figure 5D), Orai3 (Figure 5E) and STIM2 (Figure 5G) were not changed in the PTH-treated HUVECs compared with the control group. These results suggested that COL1A1 and NFATC1 may be important downstream signaling molecules of PTH-induced migration and proliferation of HUVECs.

Role of Orai1-Mediated Ca\textsuperscript{2+} Signaling in NFATC1 Translocation in PTH Effects on HUVECs

NFAT acts as a Ca\textsuperscript{2+}-sensitive transcription factor, integrating Ca\textsuperscript{2+} signaling with other pathways involved in diverse cellular functions, such as cell survival, proliferation, migration, invasion, and angiogenesis (27). After dephosphorylation by calcineurin, NFAT proteins translocate from the cytosol to the nucleus, where they bind to promoter regions to turn on the expression of numerous genes (14, 28, 29). To explore the effect of PTH on NFAT signaling in endothelial cells, we conducted immunofluorescence assays. As shown in Figures 6A–F, NFATC1 translocated to the cell nucleus in HUVECs treated with PTH, and this nuclear translocation was blocked by both the calcineurin inhibitor cyclosporin A (CsA; 1 µM) (Figure 6C) and by the selective calmodulin antagonist W7 (10 µM) (Figure 6D). These results suggested a pivotal role of PTH in activating calcineurin for NFATC1 dephosphorylation subsequently leading to nuclear translocation. We then either treated HUVECs with the SOCE inhibitor BTP2 (10 µM) (Figure 6E) or transfected HUVECs with Orai1-specific siRNA (Figure 6F) and found that NFAT nuclear translocation was inhibited in both treated groups. To confirm NFAT nuclear translocation, we also conducted fractionation experiments. Phosphorylated NFATC1
FIGURE 5 | Effect of parathyroid hormone (PTH) on mRNA expressions of COL1A1, NFATC1, Orai1, Orai2, Orai3, STIM1 and STIM2 in human umbilical vein endothelial cells (HUVECs). (A–G) After the treatment with vehicle control or 100 pM PTH for 24 h, alterations in (A) COL1A1, (B) NFATC1, (C) Orai1, (D) Orai2, (E) Orai3, (F) STIM1, (G) STIM2 mRNA levels were detected by qPCR assays in HUVECs. Messenger RNA expression was normalized to that of GAPDH. Data are shown as the mean ± SEM; n = 5 – 6. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Con.

(p-NFATC1) remains in the cytosol, but dephosphorylated NFATC1 can translocate to the nucleus (14). The cytoplasmic and nuclear components were extracted from total HUVECs lysates. As shown in Figure 6G, in agreement with our immunofluorescence data, PTH elicited nuclear translocation of NFATC1 in HUVECs. The increased NFATC1 level in the nuclear fraction was inhibited by pretreating the cells with CsA, W7, BTP2 or Orai1-specific siRNA (Figure 6H). The level of p-NFATC1 protein expression was significantly decreased in the cytosol of HUVECs treated with PTH compared with controls, but this decrease was blocked by pretreating the cells with CsA, W7, BTP2 or Orai1-specific siRNA. These results indicated that Orai1-mediated Ca^{2+} influx activates the calmodulin/calcineurin/NFATC1 signaling pathway to induce NFATC1 nuclear translocation.

PTH Regulates COL1A1 Expression by Enhancing NFATC1 Nuclear Translocation

When NFATC1 translocates from the cytosol to the nucleus, it can bind to gene promoter regions and induce the expression of numerous genes (29). Therefore, we next investigated the role of the calmodulin/calcineurin/NFATC1 signaling pathway on the regulation of COL1A1 expression. We found that PTH treatment significantly increased both the mRNA and protein expression levels of COL1A1, and these increases were significantly blocked by treatment with CsA, W7, and BTP2 (Figure 7).

Roles of COL1A1 in PTH-Increased HUVEC Migration and Proliferation

COL1A1, an α1 chain of type I collagen and the main constituent of the extracellular matrix component in tumors, is essential for specific interactions between cell surface and transmembrane molecules and is involved in the control of cellular biological activities, such as cell differentiation, proliferation, adhesion, migration, invasion, and apoptosis (30, 31). To explore the effect of COL1A1 on cell migration, we conducted wound healing assays. As shown in Figures 8A,B, PTH significantly increased the percentage of migrating HUVECs compared with that in the control group. However, knockdown of COL1A1 expression by specific siRNA transfection or pretreatment with CsA, W7, or BTP2 markedly suppressed the PTH-induced increase in HUVEC migration (Figures 8A,B). To determine whether PTH promoted the proliferation of HUVECs, we used the CCK-8 assay to assess HUVEC viability. As shown in Figure 8C, PTH significantly increased the proliferation of HUVECs compared with that in the control group. Similar to the cell migration assay results, the PTH-induced increase in
Wang et al. Parathyroid Hormone Induces Endothelial Dysfunction

FIGURE 6 | Role of Orai1-mediated store-operated Ca\(^{2+}\) entry (SOCE) in parathyroid hormone (PTH)-induced NFAT nuclear translocation in human umbilical vein endothelial cells (HUVECs). (A–F) Representative confocal microscopy images and summary data (I) showing NFATC1 distribution in HUVECs treated for 24 h with (A) vehicle control, (B) 100 pM PTH, (C) PTH + CsA (calcineurin inhibitor), (D) PTH + W7 (calmodulin antagonist), (E) PTH + BTP2 (an Orai nonspecific inhibitor) or (F) PTH + Orai1 siRNA transfection. Green fluorescence indicates NFATC1; Blue, 4′,6-diamidino-2-phenylindole (DAPI) indicates nuclei. Data are shown as the mean ± SEM; n = 4. **P < 0.01, ***P < 0.001 vs. Con or PTH analyzed by one-way analysis of variance followed by Dunnett’s multiple comparisons test. (G,H) Representative Western blot images showing fractionation assay results indicating the presence of p-NFATC1 in the cytoplasmic (Cyto, (H)) and NFATC1 in the nuclear (Nuc, (G)) extracts under the same treatment conditions as for confocal microscopy analyses. Lamin B1 is a nuclear marker; β-Tubulin is a cytoplasmic marker. (I) Summary data showing the ratio of green fluorescence intensity of NFATc-GFP in the nuclear (Nuc)/cytoplasmic (Cyto).

HUVEC proliferation was significantly inhibited by COL1A1-specific siRNA transfection or by pretreatment with CsA, W7, or BTP2 (Figure 8C). The effect of COL1A1-specific siRNA on COL1A1 protein expression was also detected by Western blotting (Figures 8D,E). Together, these results indicated that PTH treatment enhanced HUVEC migration and proliferation through the Orai1/calmodulin/calcineurin/NFATC1/COL1A1 signaling pathway (Figure 9).

DISCUSSION

Endothelial dysfunction is a critical risk factor for vascular diseases and plays a key role in atherosclerosis, hypertension, diabetes and CVD (29, 32). PTH is associated with several CVDs (5, 9, 33). However, the molecular mechanism by which PTH regulates endothelial cell proliferation and migration and endothelial dysfunction, leading to vascular disease, remains
unclear. In this study, we showed that PTH regulates SOCE activity, and we investigated the functional role of this regulation in endothelial cells. Our main findings are as follows: (1) The expression levels of Orai1 channel protein and HUVEC cell proliferation were significantly increased in HUVECs treated with PTH, whereas the expression levels of the Orai2 and Orai3 subunits remained unchanged. (2) The activity of SOCE was significantly increased in HUVECs treated with PTH, and knockdown of Orai1 protein in HUVECs suppressed SOCE activity and cell viability. (3) RNA-seq analysis revealed 1655 DEGs in PTH-treated HUVECs compared with control cells, including 823 upregulated genes and 832 downregulated genes. KEGG pathway enrichment analysis showed that the focal adhesion pathway was upregulated in the PTH-treated group, and the expression levels of two key genes, \( \text{COL1A1} \) and \( \text{NFATC1} \), whose translated proteins are involved in cell migration and proliferation, were also upregulated. (4) Nuclear translocation of NFATC1 was evoked by PTH, and this translocation was blocked by CsA, W7, BTP2, and Orai1 knockdown in HUVECs. (5) The expression levels of \( \text{COL1A1} \) mRNA and protein in HUVECs were enhanced by PTH administration, and this enhancement was blocked by CsA, W7 and BTP2. (6) HUVEC migration and proliferation were increased by PTH, and the increases in these processes were blocked by CsA, W7, BTP2 and \( \text{COL1A1} \) siRNA transfection. Together, these data suggest that PTH increases SOCE activity and downstream NFATC1 nuclear translocation in HUVECs, leading to increased \( \text{COL1A1} \) expression, which regulates HUVEC migration and proliferation (Figure 9). To our knowledge, this is the first study to report these important findings.

SOCE participates not only in relevant signaling pathways of physiological processes but also in various pathological processes. In fact, many studies have indicated that SOCE-related proteins, including Orais and STIM1, affect the vascular system in a variety of pathological conditions. The Orai1 protein, which is located in the endothelial cell plasma membrane, is involved in various dysfunctions of the endothelium (12, 29–31). For example, Orai1 and STIM1 mediate histamine-induced endothelial inflammation, and Orai1 is involved in endoplasmic reticulum stress–induced endothelial dysfunction (33, 34).
study showed that Orai1 was involved in the PTH-induced increase in SOCE activity in HUVECs, whereas Orai2 and Orai3 did not participate. These findings indicate that different components of SOCE may contribute to different responses. Orai1 is likely a key mediator in PTH-induced endothelial dysfunction in CVD.
Wang et al. Parathyroid Hormone Induces Endothelial Dysfunction

FIGURE 9 | Schematic diagram of Orai1-mediated store-operated Ca\(^{2+}\) entry (SOCE) signal transduction pathway in human umbilical vein endothelial cells (HUVECs) after parathyroid hormone (PTH) stimulation. In this proposed mechanism, PTH acts on its receptor PTHR1, a G-protein coupled receptor, to produce phospholipase C (PLC) and then inositol trisphosphate (IP\(_3\)), which stimulates its receptor to deplete Ca\(^{2+}\) stores in the endoplasmic reticulum (ER), leading to the opening of the Orai1 channel in HUVECs to induce extracellular Ca\(^{2+}\) influx via SOCE. The subsequent increase in intracellular Ca\(^{2+}\) ([Ca\(^{2+}\)]\(_i\)) causes the nuclear translocation of NFATC1 through the Ca\(^{2+}\)/calmodulin-dependent kinase 2 (CaMK-II)/calcineurin signaling pathway, and eventually induces COL1A1 overexpression and HUVEC migration and proliferation.

The calcineurin/NFAT signaling pathway is involved in the genomic regulation of many cellular processes, including the cell cycle, development, differentiation, and angiogenesis (35–37), and SOCE-mediated Ca\(^{2+}\) regulatory signaling is critical for NFAT activation and downstream signal transduction in a variety of autoimmune diseases (15, 38). But we still do not know the role of this pathway in CVD. In response to histamine stimulation, endothelial cells upregulate interleukin 8 production through the calcineurin/NFAT pathway, leading to endothelial inflammation. In the present study, we found that PTH also activated the NFATC1 pathway and increased COL1A1 expression through Orai1-mediated Ca\(^{2+}\) entry. Orai1 knockdown or calcineurin/NFAT pathway inhibitors reduced the PTH-induced NFATC1 nuclear translocation and the PTH-induced increase in COL1A1 expression. Studies from other groups have shown that COL1A1 participates in cell adhesion and motility in various diseases (39–41). Therefore, we used RNA-seq and bioinformatics analyses to find that COL1A1 transcriptome expression was increased in PTH-treated HUVECs (42, 43). COL1A1 has also been reported to be upregulated in osteoblasts via the calcineurin/NFAT signaling pathway (44). We found that the PTH-increased COL1A1 expression was also mediated via activation of the calcineurin/NFATC1 signaling pathway, thereby enhancing the migration and proliferation of HUVECs; COL1A1 knockdown or calcineurin/NFAT pathway inhibitors significantly reduced the migration and proliferation of HUVECs. Thus, our study suggests an Orai1/calcmodulin/calcineurin/NFATC1/COL1A1 signaling pathway in PTH-increased endothelial cell migration and proliferation (Figure 9).

There are some limitations to the present study because SHPT-associated vascular disease is a complex process involving interactions of primary disease, hypercalcemia, hyperphosphatemia, and parathyroid hormone abnormalities (21, 45). Therefore, further analyses using animal models is suggested, and potential therapeutic applications should be evaluated.

CONCLUSION

In conclusion, this study is the first, to our knowledge, to demonstrate that PTH increased Orai1 protein expression and Orai1-mediated SOCE activity in HUVECs, leading to the nuclear translocation of NFATC1 to subsequently enhance COL1A1 expression and COL1A1-mediated migration and proliferation of HUVECs. Our results suggest that Orai1 and the downstream calcmodulin/calcineurin/NFATC1/COL1A1 signaling pathway may play an important role in PTH-induced endothelial dysfunction and may be key potential therapeutic targets for preventing or treating SHPT-induced CVD.
DATA AVAILABILITY STATEMENT

The sequenced data presented in the study are deposited in the NCBI repository, accession number PRJNA807401.

AUTHOR CONTRIBUTIONS

SW, LX and BS contributed to the design of the study. SW, LX, HS, YW, and ZL performed the experiments. LZ, BS, YL, and KW supervised the project. SW, BS and YF wrote the manuscript. All authors participated in revising the article and approved the final manuscript.

FUNDING

The current work was supported by the Natural Science Foundation of China (Grant No. 82171127), the Natural Science Foundation of Anhui Province (Grant No. 1808085MH252), the Discipline Construction Project of Anhui Medical University (Grant No. 2021lcxk007), the Anhui Provincial Institute of Translational Medicine (Grant No. 2021hxy-C40), and the Project Funded by Scientific Research Platform and Base Upgrading Plan of Anhui Medical University (2021xjT048).

ACKNOWLEDGMENTS

The authors thank the Center for Scientific Research of Anhui Medical University for valuable help in the experiment.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.844671/full#supplementary-material

REFERENCES

1. Gregg LP, HedayaT SS. Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data? Am J Kidney Dis. (2018) 72:728–44. doi: 10.1053/j.ajkd.2017.12.007
2. Mizobuchi M, Ogata H, Koiva F. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment. Ther Apheresis Dialysis. (2019) 23:309–18. doi: 10.1111/1744-9987.12772
3. Morsy MS, Dishmon DA, Garg N, Weber KT. Secondary hyperparathyroidism in heart failure. Am J Med Sci. (2017) 354:335–8. doi: 10.1016/j.amjms.2017.02.008
4. Andres D, Coney DW, Kalantar-Rejmark L. Cardiovascular consequences of stages 3 and 4 chronic kidney disease. Endocrine Pract. (2008) 14:18–27. doi: 10.4158/EP.14.1.18
5. Khundmiri SJ, Murray RD, Lederer E. PTH and vitamin D. Annales d’endocrinologie. (2021) 2021:151–281. doi: 10.1016/j.ando.2020.02.003
6. Tomaschitz A, Ritz E, Pieske B, Fahrleitner-Pammer A, Kienreich K, Horina JH, et al. Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res. (2012) 94:10–9. doi: 10.1093/cvr/cvs092
7. Brown SJ, Ruppe MD, Tabatabai LS. The Parathyroid Gland and Heart Disease. Methodist Deakeby Cardiovasc J. (2017) 13:49–54. doi: 10.14797/mdcj-13-2-49
8. Carafoli E, Krebs J. Why Calcium? How calcium became the best communicator. J Biol Chem. (2016) 291:20849–57. doi: 10.1074/jbc.R116.735894
9. Gruson D. PTH and cardiovascular risk. Annales d’endocrinologie. (2021) 82:149–50. doi: 10.1016/j.andro.2020.02.005
10. Bollerslev J, Jóstvedt E, Rejmark L. Cardiovascular consequences of parathyroid disorders in adults. Annales d’endocrinologie. (2021) 82:151–7. doi: 10.1016/j.andro.2020.02.003
11. Pathak T, Agrawal T, Richhariya S, Sadaf S, Hasan G. Store-operated calcium entry through orai is required for transcriptional maturation of the flight circuit in drosophila. J Neurosci. (2015) 35:13784–99. doi: 10.1523/JNEUROSCI.1680-15.2015
12. Groschner K, Shresta N, Fameli N. Cardiovascular and hemostatic disorders: SOCE in cardiovascular cells: emerging targets for therapeutic intervention. Adv Exp Med Biol. (2017) 993:473–503. doi: 10.1007/978-3-319-57732-6_24
13. Garcia-Vaz E, McNelly AD, Berglund LM, Ahmad A, Gallagher JR, Duttius Andersson AM, et al. Inhibition of NFAT signaling restores microvascular endothelial function in diabetic. Mice Diabetes. (2020) 69:424–35. doi: 10.2337/db18-0870

14. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. (2005) 5:472–84. doi: 10.1038/nri1652
15. Kitao A, Sato Y, Sawada-Kitamura S, Harada K, Sasaki M, Morikawa H, et al. Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. Am J Pathol. (2009) 175:616–26. doi: 10.2353/ajpath.2009.801061
16. Park YJ, Yoo SA, Kim M, Kim WU. The role of calcium-calciunin-NFAT signaling pathway in health and autoimmune diseases. Front Immunol. (2020) 11:195. doi: 10.3389/fimmu.2020.00195
17. Liu C, Deng L, Lin J, Zhang J, Huang S, Zhao J, et al. Zinc finger protein CTCF Regulates Extracellular Matrix (ECM)-related gene expression associated with the Wnt signaling pathway in gastric cancer. Front Oncol. (2020) 10:625633. doi: 10.3389/fonc.2020.625633
18. Xian S, Chen A, Wu X, Lu C, Wu Y, Huang F, et al. Activation of activin/Smad2 and 3 signaling pathway and the potential involvement of endothelial-mesenchymal transition in the valvular damage due to rheumatic heart disease. Mol Med Rep. (2021) 23:10. doi: 10.3892/mmr.2020.11648
19. Wu W, Yang Z, Long F, Luo L, Deng Q, Wu J, et al. COL1A1 and MZB1 as the hub genes influenced the proliferation, invasion, migration and apoptosis of rectum adenocarcinoma cells by weighted correlation network analysis. Bioorg Chem. (2020) 95:103457. doi: 10.1016/j.bioorg.2019.103457
20. Guo J, Zhao R, Zhou M, Li J, Yao X, Du J, et al. TRPP2 and STIM1 form a microdomain to regulate store-operated Ca(2+) entry and blood vessel tone. Cell communication and signaling: CCS. (2020) 18:138. doi: 10.1186/s12964-020-00560-7
21. Bozik M, Diaz-Tocados JM, Bermudez-Lopez M, Forne C, Martinez C, Fernandez E, et al. Independent effects of secondary hyperparathyroidism and hyperphosphatemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrol Dialysis Transplant. (2021) gfab184. doi: 10.1093/ndt/gfab184
22. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. (2010) 26:139–40. doi: 10.1093/bioinformatics/btp616
23. López-Colomé AM, Lee-Rivera I, Benavides-Hidalgo R, López E, Paxilllin: a crossroad in pathological cell migration. J Hematol Oncol. (2017) 10:50. doi: 10.1186/s12964-017-0418-y
24. Zebda N, Dubrovskyi O, Birukov KG. Focal adhesion kinase regulation of mechanotransduction and its impact on endothelial cell functions. Microvasc Res. (2012) 83:71–81. doi: 10.1016/j.mvr.2011.06.007
25. Lee JY, Berry CT, Kim K, Sen P, Kim T, Carrer A, et al. Acetyl-CoA promotes glioblastoma cell adhesion and migration through Ca(2+)-NFAT signalling. Genes Develop. (2018) 32:497–511. doi: 10.1101/gad.311027.117
26. Kang JY, Kang N, Yang YM, Hong JH, Shin DM. The role of Ca(2+)--NFATc1 signaling and its modulation on osteoclastogenesis. Int J Mol Sci. (2020) 21:3646. doi: 10.3390/ijms21103646

27. Fu XH, Chen CZ, Wang Y, Peng YX, Wang WH, Yuan B, et al. COL1A1 affects apoptosis by regulating oxidative stress and autophagy in bovine cumulus cells. Theriogenology. (2019) 139:81–9. doi: 10.1016/j.theriogenology.2019.07.024

28. Sengupta P, Xu Y, Wang L, Widom R, Smith BD. Collagen alphal(I) gene (COL1A1) is repressed by RFX family. J Biol Chem. (2005) 280:21004–14. doi: 10.1074/jbc.M413191200

29. Wei Y, Bai S, Yao Y, Hou W, Zhu J, Fang H, et al. Orai-vascular endothelial-cadherin signaling complex regulates high-glucose exposure-induced increased permeability of mouse aortic endothelial cells. BMJ Open Diabetes Res Care. (2021) 9:e002085. doi: 10.1136/bmjdrc-2020-002085

30. Targos B, Baranska J, Pomorski P. Store-operated calcium entry in physiology and pathology of mammalian cells. Acta Biochim Pol. (2005) 52:397–409. doi: 10.18388/abp.2005_3452

31. Rode B, Bailey MA, Marthan R, Beech DJ, Guibert C. ORAI Channels as potential therapeutic targets in pulmonary hypertension. Physiology (Bethesda, Md). (2018) 33:261–8. doi: 10.1152/physiol.00116.2018

32. Fitzpatrick LA, Bilezikian JP, Silverberg SJ. Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep. (2008) 6:77–83. doi: 10.1007/s11914-008-0014-8

33. Zhou MH, Zheng H, Si H, Jin Y, Peng JM, He L, et al. Stromal interaction molecule 1 (STIM1) and Orai1 mediate histamine-evoked calcium entry and nuclear factor of activated T-cells (NFAT) signaling in human umbilical vein endothelial cells. J Biol Chem. (2014) 289:29446–56. doi: 10.1074/jbc.M114.578492

34. Yamamura H, Suzuki Y, Asai K, Imaizumi Y, Yamamura H. Oxidative stress facilitates cell death by inhibiting Orai1-mediated Ca(2+) entry in brain capillary endothelial cells. Biochim Biophys Acta. (2020) 2023:153–8. doi: 10.1016/j.bbamcr.2019.12.035

35. Heit JJ, Apelqvist AA, Gu X, Winslow MM, Neilson JR, Crabtree GR, et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature. (2006) 443:345–9. doi: 10.1038/nature05097

36. Yin Y, Du L, Li X, Zhang X, Gao Y. miR-133a-3p suppresses cell proliferation, migration, and invasion and promotes apoptosis in esophageal squamous cell carcinoma. J Cell Physiol. (2019) 234:12757–70. doi: 10.1002/jcp.27896

37. Qin JJ, Nag S, Wang W, Zhou J, Zhang WD, Wang H, et al. NFAT as cancer target: mission possible? Biochimica et biophysica acta. (2014) 1846:297–311. doi: 10.1016/j.bbcan.2014.07.009

38. Braun AP. Some assembly required: SOCE and Orai channels couple to NFAT transcriptional activity via calmodulin and calcineurin. Channels (Austin, Tex). (2014) 8:383–4. doi: 10.4161/19336950.2014.951250

39. Yang F, Zhao Z, Cai S, Ling L, Hong L, Tao L, et al. Detailed molecular mechanism and potential drugs for COL1A1 in carboplatin-resistant ovarian cancer. Front Oncol. (2020) 10:576565. doi: 10.3389/fonc.2020.576565

40. Guo Y, Lu G, Mao H, Zhou S, Tong X, Wu J, et al. miR-133b Suppresses invasion and migration of gastric cancer cells via the COL1A1/TGF-β Axis. Onco Targets Ther. (2020) 13:7985–95. doi: 10.2147/OTT.S249667

41. Wang Q, Shi L, Shi K, Yuan B, Cao G, Kong C, et al. CircCSP1 functions as a ceRNA to promote colorectal carcinoma cell EMT and liver metastasis by upregulating COL1A1. Front Oncol. (2020) 10:850. doi: 10.3389/fonc.2020.00850

42. Brown J, Pirrung M, McCue LA. FQC Dashboard: integrates FastQC results into a web-based, interactive, and extensible FASTQ quality control tool. Bioinformatics (Oxford, England). (2017) 33:3137–9. doi: 10.1093/bioinformatics/btx373

43. Zhou Y, Zhou B, Puche L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. (2019) 10:1523. doi: 10.1038/s41467-019-09234-6

44. Liu C, Cao Z, Zhang W, Tickner J, Qiu H, Wang C, et al. Lumichrome inhibits osteoclastogenesis and bone resorption through suppressing RANKL-induced NFAT activation and calcium signaling. J Cell Physiol. (2018) 233:8971–83. doi: 10.1002/jcp.26841

45. Torres PA, De Broe M. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney Int. (2012) 82:19–25. doi: 10.1038/ki.2012.69

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Xu, Wu, Shen, Lin, Fang, Zhang, Shen, Liu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.